Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs
IW-3718 Development Discontinued After Interim Analysis
Executive Summary
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
You may also be interested in...
Stockwatch: Batsu Games − Drug And Vaccine Development
Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.
Ionis Buys Out Akcea As Cardiovascular Pipeline Blooms
The RNA-drug developer, which is buying the approximately 24% of Akcea it doesn't already own for around $500m, highlighted the maturing pipeline in a cardiovascular overview.
Teva Leapfrogs Mylan And Sandoz On Linaclotide
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Need a specific report? 1000+ reports available
Buy Reports